Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 2Colonic Neoplasms 2Thyroid Neoplasms 1Polycystic Ovary Syndrome 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Hypothyroidism 1Hyperphagia 1Hematologic Neoplasms 1Goiter 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × Glucose × Clear all
NCT01384877 2019-07-12

Subcutaneous Lidocaine For Cancer-Related Pain

British Columbia Cancer Agency

Phase 2/3 Completed
33 enrolled 16 charts

Cancer Pain, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡